The pericarditis market size was valued at USD 2.57 Billion in 2025, driven by the rising prevalence of pericarditis across the 8 major markets. The market is expected to grow at a CAGR of 5.24% during the forecast period of 2026-2035, reaching a value of USD 4.28 Billion by 2035.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
5.24%
Value in USD Billion
2026-2035
*this image is indicative*
Pericarditis is characterized by the inflammation of the pericardium (sac surrounding the heart) caused by various disorders such as myocardial infarction, infection, metabolic disorders, and tumors. Pericarditis is the most common pericardial disease, leading to 5.4-26 hospitalizations per 100,000 individuals annually in the United States. Recurrent pericarditis occurs in 30% of patients having acute pericarditis, with treatment lasting up to 7 years. The rising prevalence of the disease is expected to augment the market size in the forecast period.
The surge in approvals from health regulatory agencies also drives the pericarditis market growth. In February 2024, the United States Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to a small molecule drug candidate called CardiolRx™ to treat pericarditis. Developed by Cardiol Therapeutics Inc., a clinical-stage life sciences company in the United States, the drug candidate is undergoing Phase II clinical trials for recurrent pericarditis and acute myocarditis.
The emergence of novel therapies to treat the condition and address a wider section of patients is expected to fuel the market demand in coming years. Increased research and development initiatives along with investments made by the key players is projected to boost the market size. Heightened awareness of heart health among patients through campaigns and trends is another significant factor contributing to the increasing market size.
The EMR’s report titled “Pericarditis Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnostic Method
In terms of diagnostic methods, the market is segmented into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), and X-ray, among others. This segmentation ensures diagnosis and evaluation of pericarditis to facilitate appropriate treatment interventions.
Market Breakup by Drug Type
Based on the drug type, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and others. NSAIDs are used to reduce inflammation and relieve pain associated with pericarditis. Colchicine has been effective in preventing recurrent pericarditis episodes.
Market Breakup by End User
Based on end users, the pericarditis market share is segmented hospitals and clinics, as well as medical institutes and research laboratories, among others.
Market Breakup by Distribution Channels
Major distribution channels of the market include hospital pharmacies, retail pharmacies, online pharmacies, and others. Increasing digitization has led to increased preference for online pharmacies amongst patients.
Market Breakup by Region
The market report includes 8 major markets projected to show significant growth in the forecast period. The segmentation based on the region covers the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America holds a high market value which can be attributed to the rising geriatric population base in the region. In addition, the presence of an advanced healthcare system and the increased prevalence of cardiovascular diseases are anticipated to propel the market growth.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 2.57 Billion in 2025 driven by the rising prevalence of pericarditis across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.24% during the forecast period of 2026-2035, likely to reach a market value of USD 4.28 Billion by 2035.
The rise in cardiovascular diseases and growing awareness surrounding heart health are fuelling the demand for the market.
One of the significant trends in the market is the surge in drug approvals from health regulatory agencies such as the FDA. In February 2024, the United States FDA granted Orphan Drug Designation (ODD) to Cardiol Therapeutics' CardiolRx™, a small molecule drug candidate developed to treat pericarditis.
Based on the diagnostic methods, the market is segmented into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), and X-ray.
Based on the drug type, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and others.
Major end users of the market include hospitals and clinics, as well as medical institutes and research laboratories.
Major distribution channels of the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are Kiniksa Pharmaceuticals, Pfizer Inc., Bayer AG, AstraZeneca Plc, Sanofi, Johnson and Johnson Services, Inc., Merck & Co., Inc., Allergan Plc., Novartis AG, and Perkin Elmer Inc.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostic Method |
|
| Breakup by Drug Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share